ライフサイエンスコーパス: idarucizumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 l-vein bleeding time, which were reversed by idarucizumab.

2 Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g pl

3 m analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B).

4 for dTT was 1.01 with placebo, 0.26 with 1 g idarucizumab (74% reduction), 0.06 with 2 g idarucizumab

5 idarucizumab (74% reduction), 0.06 with 2 g idarucizumab (94% reduction), 0.02 with 4 g idarucizumab

6 idarucizumab (94% reduction), 0.02 with 4 g idarucizumab (98% reduction), and 0.01 with 5 g plus 2.5

7 98% reduction), and 0.01 with 5 g plus 2.5 g idarucizumab (99% reduction).

8 Idarucizumab, a monoclonal antibody fragment, was develo

9 ombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoa

10 We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran

11 Idarucizumab, an antibody fragment, was developed to rev

12 o determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagula

13 5 g plus 2.5 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11

14 ed into the 4 g idarucizumab group (eight to idarucizumab and three to placebo).

15 Idarucizumab completely reversed the anticoagulant effec

16 roved humanized monoclonal antibody fragment idarucizumab for reversing the effects of dabigatran, th

17 ability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects o

18 ch group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to p

19 and hot flushes), one in the 5 g plus 2.5 g idarucizumab group (epistaxis); one receiving placebo (i

20 ported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flush

21 into each of the 1 g, 2 g, or 5 g plus 2.5 g idarucizumab groups (nine to idarucizumab and three to p

22 Idarucizumab immediately and completely reversed dabigat

23 Idarucizumab in equimolar dose prevented excess hematoma

24 Idarucizumab is a monoclonal antibody fragment that bind

25 Idarucizumab is available as an antidote to rapidly reve

26 Idarucizumab normalized the test results in 88 to 98% of

27 n within 4 hours after the administration of idarucizumab, on the basis of the determination at a cen

28 n within 4 hours after the administration of idarucizumab, on the basis of the diluted thrombin time

29 mly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number gene

30 Thus, idarucizumab prevents excess intracerebral hematoma form

31 In emergency situations, idarucizumab rapidly, durably, and safely reversed the a

32 In more extensive ICH, idarucizumab significantly reduced mortality.

33 These phase 1 results show that idarucizumab was associated with immediate, complete, an

34 tudy to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。